Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Eurartesim
Eurartesim 160 mg/20 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 7
HOS-123033 · Präparat HOS-095623
Oral contraceptives
When co-administered to healthy women, Eurartesim exerted only a minimum effect on an
estrogen/progestinic combination oral contraceptive treatment increasing the ethynilestradiol rate of
absorption (expressed by geometric mean Cmax) of about 28% but not significantly changing the
exposure to ethynilestradiol and levonorgestrel and not influencing contraception activity as
demonstrated by the similar plasma concentrations of follicle stimulating hormone (FSH), luteinizing
hormone (LH) and progesterone observed after oral contraceptive treatment with or without
concomitant Eurartesim administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) levonorgestrel (HOS-089677)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 6d376a8389e934674385263ef9c46d6f4d38f0c4dee313c1d0f86fdaf1607c5c · Zeichen 3878–4503 im Abschnitt
Wechselwirkungen · Eurartesim
Eurartesim 320 mg/40 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 22
HOS-123074 · Präparat HOS-095623
Oral contraceptives
When co-administered to healthy women, Eurartesim exerted only a minimum effect on an
estrogen/progestinic combination oral contraceptive treatment increasing the ethynilestradiol rate of
absorption (expressed by geometric mean Cmax) of about 28% but not significantly changing the
exposure to ethynilestradiol and levonorgestrel and not influencing contraception activity as
demonstrated by the similar plasma concentrations of follicle stimulating hormone (FSH), luteinizing
hormone (LH) and progesterone observed after oral contraceptive treatment with or without concomitant
Eurartesim administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) levonorgestrel (HOS-089677)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 0f960b9715151a40099385e254ca71fc82fdac5a50c53cbbd78c0358bdd963bb · Zeichen 3875–4500 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-129279 · Präparat HOS-096703
14
available for this dose adjustment, see
section 4.2).
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no Pharmacodynamic
Norgestromin EE ↔ effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC ↑ 3% Follicle Stimulating Hormone (FSH) and
Cmax ↓ 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Triumeq.
NGMN ↔
AUC ↓ 2%
Cmax ↓ 11%
Antihypertensive
Riociguat/Abacavir Riociguat ↑ Riociguat dose may need to be reduced,
consult the riociguat prescribing
In vitro, abacavir inhibits
information for dosing
CYP1A1. Concomitant
recommendations.
administration of a single
dose of riociguat (0.5 mg)
to HIV patients receiving
Triumeq led to an
approximately three-fold
higher riociguat AUC(0-∞)
when compared to
historical riociguat
AUC(0-∞) reported in
healthy subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) riociguat (HOS-086293) ethinyl estradiol (HOS-088135) luteinizing hormone (HOS-090752)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 43410c94b6dbbc0219581d49891490b32c1f5a61b551a7d4fe3c782cf1266f3e · Zeichen 29393–31452 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50–52
HOS-129364 · Präparat HOS-096703
50
(Complex binding to The stated reductions in dolutegravir
polyvalent ions) exposure were observed with the intake
Multivitamins (containing Dolutegravir ↓ of dolutegravir and these supplements
calcium, iron and magnesium) AUC ↓ 33% during fasted conditions. In fed state, the
/Dolutegravir Cmax ↓ 35% changes in exposure following intake
C24 ↓ 32% together with calcium or iron
supplements were modified by the food
effect, resulting in an exposure similar to
that obtained with dolutegravir
administered in the fasted state.
Corticosteroids
Prednisone Dolutegravir ↔ No dose adjustment is necessary.
AUC ↑ 11%
Cmax ↑ 6%
Cτ ↑ 17%
Antidiabetics
Metformin/Dolutegravir Metformin ↑ A dose adjustment of metformin should
Dolutegravir ↔ be considered when starting and
When co-administered stopping coadministration of
with dolutegravir 50mg dolutegravir with metformin, to maintain
QD: glycaemic control. In patients with
Metformin moderate renal impairment a dose
AUC ↑ 79% adjustment of metformin should be
Cmax ↑ 66% considered when coadministered with
When co-administered dolutegravir, because of the increased
with dolutegravir 50mg risk for lactic acidosis in patients with
BID: moderate renal impairment due to
Metformin increased metformin concentration
AUC ↑ 145 % (section 4.4).
Cmax ↑ 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
(Not studied, decrease should be adjusted when co-
expected due to induction administered with St. John’s wort.
of UGT1A1 and CYP3A
enzymes, a similar Dosing recommendations are provided
reduction in exposure as in Table 2 (see section 4.2)
observed with
carbamazepine is
expected)
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no Pharmacodynamic
Norgestromin EE ↔ effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC ↑ 3% Follicle Stimulating Hormone (FSH) and
Cmax ↓ 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Triumeq.
NGMN ↔
AUC ↓ 2%
Cmax ↓ 11%
Antihypertensive
Riociguat/Abacavir Riociguat ↑ Riociguat dose may need to be reduced,
consult the riociguat prescribing
In vitro, abacavir inhibits
information for dosing
CYP1A1. Concomitant
recommendations.
administration of a single
51
dose of riociguat (0.5 mg)
to HIV patients receiving
Triumeq led to an
approximately three-fold
higher riociguat AUC(0-∞)
when compared to
historical riociguat
AUC(0-∞) reported in
healthy subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) riociguat (HOS-086293) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 4f0d85e516680fd44841c8a2084bad237df81c83647e075fbfa5f388b51c50c4 · Zeichen 22392–27416 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-142843 · Präparat HOS-098886
11
Multivitamins (containing Dolutegravir during fasted conditions. In fed state, the
calcium, iron and magnesium) AUC 33% changes in exposure following intake
/Dolutegravir Cmax 35% together with calcium or iron
(fasted intake) C24 32% supplements were modified by the food
(Complex binding to effect, resulting in an exposure similar to
polyvalent ions) that obtained with dolutegravir
administered in the fasted state.
Proton pump inhibitors
Omeprazole Dolutegravir No dosage adjustment necessary.
Corticosteroids
Prednisone/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin/Dolutegravir Metformin A dose adjustment of metformin should
Dolutegravir be considered when starting and
When co-administered stopping coadministration of Dovato
with dolutegravir 50 mg with metformin, to maintain glycaemic
QD: control. In patients with moderate renal
Metformin impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with Dovato, because of
When co-administered the increased risk for lactic acidosis in
with dolutegravir 50 mg patients with moderate renal impairment
BID: due to increased metformin
Metformin concentration (section 4.4).
AUC 145 %
Cmax 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir The recommended dose of dolutegravir
(Not studied, decrease is 50 mg twice daily when co-
expected due to induction administered with St. John’s wort. As
of UGT1A1 and CYP3A Dovato is a fixed-dose tablet, an
enzymes, a similar additional 50 mg tablet of dolutegravir
reduction in exposure as should be administered, approximately
observed with 12 hours after Dovato for the duration of
carbamazepine is the St. John’s wort co-administration (a
expected). separate formulation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no pharmacodynamic
Norgestromin EE effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC 3% Follicle Stimulating Hormone (FSH) and
Cmax 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Dovato.
NGMN
AUC 2%
Cmax 11%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 2f6766181d55d8513097e83ade1239e25819402a3fdabb28f23368f6b03130e3 · Zeichen 23358–27625 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.